Garassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., . . . Paz-Ares, L. (2023). Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO clinical and research reports, 4(1), 100431. https://doi.org/10.1016/j.jtocrr.2022.100431
Citácia podle Chicago (17th ed.)Garassino, Marina C., et al. "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC." JTO Clinical and Research Reports 4, no. 1 (2023): 100431. https://doi.org/10.1016/j.jtocrr.2022.100431.
Citácia podľa MLA (8th ed.)Garassino, Marina C., et al. "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC." JTO Clinical and Research Reports, vol. 4, no. 1, 2023, p. 100431, https://doi.org/10.1016/j.jtocrr.2022.100431.